Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study

Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook a prospective interventional open-label cohort study to evaluate the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirenga, Bruce J., Mugenyi, Levicatus, Sánchez-Rico, Marina, Kyobe, Henry, Muttamba, Winters, Mugume, Raymond, Mwesigwa, Eliya, Kalimo, Ezra, Nyombi, Vicky, Segawa, Ivan, Namakula, Loryndah Olive, Sekibira, Rogers, Kabweru, Wilberforce, Byanyima, Rosemary, Aanyu, Hellen, Byakika-Kibwika, Pauline, Mwebesa, Henry G., Hoertel, Nicolas, Bazeyo, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982784/
https://www.ncbi.nlm.nih.gov/pubmed/36869228
http://dx.doi.org/10.1038/s41380-023-02004-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982784/
https://www.ncbi.nlm.nih.gov/pubmed/36869228
http://dx.doi.org/10.1038/s41380-023-02004-3

Ejemplares similares